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Abstract
Background: Pseudomonas aeruginosa is a common pathogen in chronic respiratory tract infections. It typically makes 
a biofilm, which makes treatment of these infections difficult. In this study, we investigated the inhibitory effects of N-
acetylcysteine (NAC) on biofilms produced by P. aeruginosa.
Results: We found that minimum inhibitory concentrations (MICs) of NAC for most isolates of P. aeruginosa were 10 to 
40 mg/ml, the combination of NAC and ciprofloxacin (CIP) demonstrated either synergy (50%) or no interaction (50%) 
against the P. aeruginosa strains. NAC at 0.5 mg/ml could detach mature P. aeruginosa biofilms. Disruption was 
proportional to NAC concentrations, and biofilms were completely disrupted at 10 mg/ml NAC. Analysis using 
COMSTAT software also showed that PAO1 biofilm biomass decreased and its heterogeneity increased as NAC 
concentration increased. NAC and ciprofloxacin showed significant killing of P. aeruginosa in biofilms at 2.5 mg/ml and 
> 2 MIC, respectively (p < 0.01). NAC-ciprofloxacin combinations consistently decreased viable biofilm-associated 
bacteria relative to the control; this combination was synergistic at NAC of 0.5 mg/ml and CIP at 1/2MIC (p < 0.01).  
Extracellular polysaccharides (EPS) production by P. aeruginosa also decreased by 27.64% and 44.59% at NAC 
concentrations of 0.5 mg/ml and 1 mg/ml.
Conclusions: NAC has anti-bacterial properties against P. aeruginosa and may detach P. aeruginosa biofilms. Use of NAC 
may be a new strategy for the treatment of biofilm-associated chronic respiratory infections due to P. aeruginosa, 
although it would be appropriate to conduct clinical studies to confirm this.
Background
Pseudomonas aeruginosa is a known common pathogen
in respiratory tract infections. These diseases are usually
chronic, such as pulmonary infections in intubated
patients and for patients with cystic fibrosis (CF), bron-
chiectasis, diffuse panbronchiolitis [1,2] and chronic
obstructive pulmonary disease (COPD). One reason why
treating these infections is difficult is the production of
biofilms by P. aeruginosa [3]. Organisms in the biofilm
become more resistant than planktonic bacteria to physi-
cal and chemical attacks, such as by chemotherapeutic
reagents. Discovering substances that inhibit biofilm for-
mation and/or disrupt established biofilms is essential for
treating these diseases.
N-acetylcysteine (NAC) is a mucolytic agent that has
anti-bacterial properties. NAC also decreases biofilm for-
mation by a variety of bacteria [4-6] and reduces the pro-
duction of an extracellular polysaccharide matrix, while
promoting the disruption of mature biofilms [4,7]. The
effect of NAC on P. aeruginosa biofilms has not been
extensively studied, and a better understanding of bacte-
rial responses to NAC may facilitate its use as a biofilm
inhibitor. Thus, we investigated the effects of NAC for (i)
anti-bacterial properties, (ii) detachment of biofilms, (iii)
viable cells in biofilms and (iv) production of extracellular
polysaccharides (EPS) by P. aeruginosa.
Results
Susceptibility of P. aeruginosa strains to NAC and the in 
vitro interactive effects of NAC and ciprofloxacin
Twenty P. aeruginosa strains were isolated from respira-
tory samples. The minimum inhibitory concentrations
(MICs) of NAC for 18 P. aeruginosa isolates were 10 to 40
mg/ml, and MICs for another 2 isolates were > 40 mg/ml.
The combination of NAC and ciprofloxacin demon-
strated either synergy (50%) or no interaction (50%)
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observed.
Interpretations of biofilm production
Using the criteria of Stepanovic et al, P. aeruginosa strains
were divided into the following categories: 3 (15%) were
weak biofilm producers; 10 (50%) were moderate biofilm
producers; 7 (35%) were strong biofilm producers.
Effects of NAC on biofilms of P. aeruginosa PAO1 and 
quantitative analysis using COMSTAT software
As shown in Figure 1, biofilms were observed using con-
focal laser scanning microscopy (CLSM) and three-
dimensional images were reconstructed by Olympus
FV10-ASM1.7 Software. A GFP-plasmid was inserted
into PAO1, which allowed the detection of live bacteria
by fluorescence. Observed by CLSM, PAO1 grew in a
characteristic pattern with a lawn of bacterial growth on
the surface. These results showed that NAC disrupted
and inhibited PAO1 biofilms, fluorescence and thickness
decreased after exposure to NAC, and there was an NAC
dose-dependent effect. Almost no fluorescence was
detected after 10 mg/ml NAC treatment, indicating that
very few to no live PAO1 were present. Decreased GFP
detection levels were associated with increasing concen-
trations of NAC in each fixed scanning area (Figure 2).
When analyzed using COMSTAT software, P. aerugi-
nosa biofilms showed significant structural differences in
the presence of the NAC regimen (Table 1). The biomass,
substratum coverage, average thickness, maximum thick-
ness and surface area of the biomass all decreased for bio-
films grown in the presence of NAC. The surface to
volume ratio and roughness coefficients showed the
opposite trends.
Viable cell counts after treatment with NAC combined with 
CIP
Results for viable cell counts in biofilms are shown in
Table 2. NAC had an independent anti-microbial effect
on biofilm-associated P. aeruginosa at 2.5 mg/ml (p <
0.01). Compared with the control, there were significant
differences at ciprofloxacin (CIP) of 2 MIC, 4 MIC or 8
MIC (p < 0.01). NAC-ciprofloxacin combinations consis-
tently decreased viable biofilm-associated bacterial
counts relative to the control. This combination was syn-
ergistic at NAC of 0.5 mg/ml and CIP of 1/2MIC (p <
0.01).
Effect of NAC on extracellular polysaccharides (EPS) 
production
EPS production by P. aeruginosa decreased significantly
in the presence of NAC. The amount of EPS produced by
P. aeruginosa decreased, on average, by as much as
27.46% and 44.59% in the presence of 0.5 mg/ml and 1
mg/ml NAC, respectively.
Discussion
NAC is considered a non-antibiotic drug that has anti-
bacterial properties. In 1977, Parry and Neu [8] found
that NAC had the characteristics to inhibit the growth of
both gram-positive and gram-negative bacteria, includ-
ing S. aureus, P. aeruginosa, K. pneumoniae and Enter-
obacter clocae. P. aeruginosa was more susceptible than
most of the other tested microorganisms (MIC 2-20 μg/
ml), P. aeruginosa strains were inhibited synergistically by
NAC and carbenicillin or ticarcillin. Roberts and Cole [9]
found that 2%-5% of NAC was anti-bactericidal against P.
aeruginosa, the effect of the carbenicillin on P. aeruginosa
was augmented by low concentrations of NAC, and the
MIC of the organisms to carbenicillin was reduced from
16 μg/ml to 1 μg/ml in the presence of one per cent NAC.
The mechanism for the anti-bacterial effect of NAC may
be that it acts by competitively inhibiting amino acid
(cysteine) utilization or, by virtue of possessing a sulfhy-
dryl group, may react with bacterial cell proteins. Our
results are consistent with those of Roberts and Cole, as
most of the P. aeruginosa strains were inhibited at con-
centrations < 40 mg/ml of NAC, and a higher percentage
of synergistic combinations with NAC was observed with
ciprofloxacin (50%). This means that NAC and ciproflox-
acin may be used together to treat P. aeruginosa infec-
tions.
Due to its ability to produce a biofilm, P. aeruginosa is
responsible for some chronic pulmonary infections, such
as those in cystic fibrosis (CF), bronchiectasis and
chronic obstructive pulmonary disease (COPD). It also
implicates that the infections are associated with endo-
tracheal tubes [10,11]. P. aeruginosa eventually causes
infections in most patients with CF, and once a chronic
infection is established, eradication of P. aeruginosa
strains is nearly impossible. Patients with bronchiectasis
who are colonized by P. aeruginosa exhibit more
advanced diseases and more severe impairments of pul-
monary function compared with those who remain free
of colonization [12-14]. Some observations suggest that P.
aeruginosa is a more common cause of infection as
COPD advances [15,16]. Recently, Martínez-Solano et al.
[17] showed that patients with COPD were usually
infected with at least 1 P. aeruginosa clone that remained
in the lungs for years. During chronic infection, each
clone diversified, and isolated from samples of infected
lungs tended to produce more biofilm compared with the
isolation from blood samples. The structure and physio-
logical characteristics of a biofilm confer an inherent
resistance to anti-microbial agents. The MICs of anti-
microbial agents can be increased 100- to 1000-fold when
bacteria grow in biofilms as compared to planktonic bac-
teria [18]. Therapy almost always fails to eradicate the
bacteria in biofilms. Therefore, it is important to search
for an effective drug to eradicate the biofilm.
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Figure 1 Biofilms of P. aeruginosa PAO1 expressing a GFP plasmid (pMRP9-1) exposed to NAC (1-1, 1-2, 1-3, 1-4, 1-5, 1-6 showed different 
concentrations). CLSM was used to create three-dimensional reconstructions of the PAO1 biofilms. Each side of image was 210 μm.
1-1˖control            1-2˖NAC0.5mg/ml
1-3˖NAC1mg/ml               1-4˖NAC2.5mg/ml
1-5˖NAC5mg/ml            1-6˖NAC10mg/ml
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biofilm formation by a variety of bacteria [4-6] and that it
inhibited bacterial adherence, reduced the production of
extracellular polysaccharide matrix, while promoting the
disruption of mature biofilms, and reduced sessile cell
viability [4,7]. Olofsson [7] studied the biofilms of 10 bac-
terial strains isolated from a paper mill. These results
showed that EPS production decreased significantly in
the presence of NAC (0.25 mg/ml). Although the growth
didn't affected the most of tested bacteria, the average
reduction in the amount of EPS produced was 58% ± 20%;
the presence of NAC reduced the number of attached
multi-species community bacteria by as much as 76% ±
46%. There is only one article demonstrated the inhibi-
tory effect of NAC on P. aeruginosa adherence and bio-
film formation in vitro by the number of viable cell counts
previously, and also revealed that ciprofloxacin/NAC
combination showed the highest ability to inhibit biofilm
synthesis and disrupt preformed mature biofilms [19]. In
our research, inhibitory effects of drugs on biofilms not
only determined by the viable count technique, but also
were imaged using CLSM and quantified biofilm struc-
tures by COMSTAT program, EPS production in the
presence of NAC also be examined quantitatively. CLSM
can provide three-dimensional, noninvasive inspection
and computer reconstruction of mature biofilms without
appreciable distortion of architecture in a manner similar
to computer-assisted tomography and magnetic reso-
nance imaging methods. COMSTAT comprises some fea-
tures for quantifying three-dimensional biofilm image
stacks [20]. Biomass represents the overall volume of the
biofilm, substratum coverage reflects how efficiently the
substratum is colonized by bacteria of the population, the
surface area of biomass is the area which summation of
all biomass voxel surfaces exposed to the background, the
surface to volume ratio is the surface area divided by the
bio-volume which indicates how the biofilm adapts to the
environment, roughness provides a measure of how
much the thickness of the biofilm varies, and it is also an
indicator of biofilm heterogeneity. Our results showed
that NAC dispersed the biofilms formed by P. aeruginosa.
By visual inspection of CLSM images, NAC disrupted
and inhibited PAO1 biofilms, fluorescence and thickness
decreased after exposure to NAC and there were dose-
dependent effects. Biofilms were nearly detached at 10
mg/ml NAC. Using COMSTAT software, the PAO1 bio-
film biomass decreased and its heterogeneity increased
gradually in direct proportion to the NAC concentration.
NAC also had an independent anti-microbial effect on
biofilm-associated P. aeruginosa at 2.5 mg/ml (P <0.01)
and had a synergistic effect with CIP. Bacterial exopoly-
saccharides are the main component of the biofilm,
which creates an efficient scavenging system for trapping
and concentrating essential minerals and nutrients from
the surrounding environment. Our research showed that
the amounts of EPS produced by P. aeruginosa strains
were also significantly inhibited by 0.5 and 1 mg/ml of
Figure 2 Fluorescence intensity in each fixed CLSM scanning area 
after treatment with NAC. NAC at 1 mg/ml, 2.5 mg/ml and 5 mg/ml 
significantly decreased the fluorescence of PAO1 biofilms after 24 

































Table 1: Effects of NAC (mg/ml) on biofilm structures of PAO1
Features control NAC 0.5 NAC 1 NAC 2.5 NAC 5
Biomass (μm3/μm2) 2.79 ± 0.64 1.63* ± 0.46 0.98* ± 0.57 0.34* ± 0.17 0.23* ± 0.12
Substratum coverage 0.52 ± 0.19 0.34 ± 0.11 0.35 ± 0.19 0.20* ± 0.08 0.21* ± 0.11
Average thickness (μm) 2.70 ± 0.80 1.47* ± 0.47 0.75* ± 0.51 0.19* ± 0.16 0.01* ± 0.01
Maximum thickness (μm) 10.20 ± 1.64 8.40* ± 1.92 5.20* ± 1.64 3.00* ± 0.80 1.60* ± 0.48
Surface area of 
biomass (μm2)
162515.9 ± 27990.3 99499.0* ± 25130.4 102665.0* ± 50400.6 49869.1* ± 24393.6 41504.3* ± 18129.7
Surface to volume ratio 
(μm2/μm3)
1.39 ± 0.33 1.41 ± 0.12 2.66* ± 0.56 3.64* ± 0.78 4.47* ± 0.66
Roughness coefficient 1.12 ± 0.19 1.43 ± 0.14 1.53* ± 0.27 1.72* ± 0.25 1.97* ± 0.02
Note: n = 10 image stacks, *compared with control, P < 0.01
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may be a potent agent for treating P. aeruginosa biofilms
associated infections, and can be used in combination
with ciprofloxacin.
Stafanger [21] studied the effect of peroral NAC in
patients with cystic fibrosis and chronic pulmonary P.
aeruginosa infection, a significant improvement of the
spirometric values was proved after NAC treatment in
the patients with peak expiratory flow rate below or equal
to 70% of predicted normal values. Stey [22] reviewed the
publications on the effect of oral NAC in chronic bron-
chitis, eleven randomized controlled NAC trials were
analysed (a total of 2,011 patients), concluded that oral
NAC reduced the risk of exacerbation and improved
symptoms in patients with chronic bronchitis compared
with palcebo. But the benefit it achieved still remains
unclear. We are not sure whether it took into account the
other elements such as anti-bacterial activities and detach
biofilms or not? It needs further study.
NAC can be administered by nebulization or direct
instillation, orally or intravenously. The concentrations
tested in our study are much higher than those reach in
serum when administer by an intravenous or oral route.
Nevertheless, it may be possible that using local respira-
tory application (10% solution may be used undiluted for
inhalation) obtains useful concentrations to disrupt bio-
films and control biofilm-associated infections of P.
aeruginosa.
Conclusions
In conclusion, our results suggest that NAC has anti-bac-
terial properties against P. aeruginosa and may detach P.
aeruginosa biofilms. It may be a new strategy for the
treatment of biofilm-associated chronic respiratory infec-
tions, although it would be appropriate to conduct in vivo
animal models and clinical studies to confirm this.
Methods
Bacterial strains
P. aeruginosa PAO1 expressing a green fluorescent pro-
tein (GFP) plasmid (pMRP9-1) was kindly donated by Dr.
E. P. Greenberg (University of Washington, Seattle). An
additional 20 strains of P. aeruginosa isolated from respi-
ratory samples were studied.
Determination of minimum inhibitory concentrations (MIC) 
and drug-drug interactions
Crystalline NAC (Sigma-Aldrich, USA) was dissolved in
distilled water to make a 100 mg/ml solution; the pH of
solution was adjusted to 7.2 before use. Stock solution of
ciprofloxacin (National Institute for the Control of Phar-
maceutical and Biological Products, China) was prepared
at concentrations of 4096 μg/ml in the distilled water.
MICs of NAC and ciprofloxacin were determined using
a broth micro-dilution assay according to Clinical Labo-
ratory Standards Institute (CLSI) guidelines [23]. Each
well of a 96-well microtiter plate containing 100 μl from a
series of diluted NAC with Mueller-Hintor broth was
inoculated with 100 μl of P. aeruginosa suspension (6-
hour broth cultures); the final inoculum was 5 × 105 CFU/
ml. After 20 h incubation in air at 35°C, the wells were
inspected for microbial growth and the MIC was defined
as the lowest concentration that inhibited the growth of
bacteria. Positive (bacterial suspension) and negative
(broth) controls were also included.
In vitro antibacterial activities of ciprofloxacin in com-
bination with NAC were determined by chequerboard
MIC assay as previously described [24]. Mueller-Hinton
broth was used. Seven doubling dilutions of NAC and 11
doubling dilutions of ciprofloxacin were tested. After
drug dilution, microbroth dilution plates were inoculated
with each organism to yield the appropriate density (105
CFU/ml) in a 100 μl final volume and incubated for 20 h
at 35°C in ambient air. The fractional inhibitory concen-
tration index (FICI) was calculated for each combination
using the following formula: FICA + FICB = FICI, where
FICA = MIC of drug A in combination/MIC of drug A
alone, and FICB = MIC of drug B in combination/MIC of
drug B alone. The FICI was interpreted as follows: syn-
ergy = FICI ≤ 0.5; no interaction = FICI >0.5-≤ 4; antago-
nism = FICI > 4.
Table 2: Viable counts of P. aeruginosa biofilm bacteria treated with NAC combined with ciprofloxacin (lg [CFU/cm2])
NAC (mg/ml) ciprofloxacin (MIC)
0 1/2 1 2 4 8
0 7.11 ± 0.34 6.96 ± 0.34 6.95 ± 0.31 6.84 ± 0.32 6.76 ± 0.29 6.60 ± 0.30
0.5 6.97 ± 0.31 6.70 ± 0.31 6.65* ± 0.33 6.40* ± 0.46 6.37* ± 0.33 6.06* ± 0.48
1 6.87 ± 0.34 6.58* ± 0.26 6.47* ± 0.33 6.23* ± 0.37 5.94* ± 0.56 5.62* ± 0.59
2.5 6.45* ± 0.27 6.22* ± 0.25 6.15* ± 0.26 6.03* ± 0.35 5.76* ± 0.58 5.05* ± 0.35
Note: n = 20 strains, *compared with NAC at 0 mg/ml and the same concentration of ciprofloxacin, P < 0.01
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Biofilm production was determined using a spectropho-
tometric method described by Stepanovic et al [25].
Briefly, stationary-phase 18-h cultures of P. aeruginosa
were diluted with fresh trypticase soy broth (TSB), and
standardized to contain 1 × 106 CFU/ml. Aliquots (0.2
ml) of the diluted cultures were added to 96-well sterile
flat-bottom polystyrene tissue culture plates (Costar,
USA). After 24 h incubation at 37°C, the contents of the
tissue culture plates were gently aspirated, then washed 3
times with sterile PBS (pH 7.2). Slime and adherent
organisms were fixed by 200 μl of 99% methanol for 20
min, stained with 200 μl crystal violet (1%) for 20 min.
Excess stain was removed by placing the plates under
running distilled water, and then the plates were air dried.
The dye bound to the cells was resolubilized with 160 μl
of 95% ethanol. The optical density of the stained adher-
ent films was read with a microplate Reader (Pulang New
Technology Corporation, China) at a wavelength of 570
nm. Measurements were performed in triplicate and
repeated 3 times. Interpretation of biofilm production
was according to the criteria of Stepanovic et al [25]
(Table 3).
PAO1 biofilm analysis using CLSM
TSB (4 ml) was dispensed in a culture dish containing a
sterile cover slip (MatTek, USA). Then, 50 μl of a bacterial
suspension (1.5 × 108 CFU/ml) was inoculated into the
dish and incubated aerobically at 37°C for 6 days. The
biofilms deposited on cover slips were gently rinsed with
sterile PBS to remove bacterial cells, except for those
included in the biofilm. After rinsing, the biofilm was
soaked in a diluent containing NAC (0, 0.5, 1, 2.5, 5, 10
mg/ml) for 24 h at 37°C. After rinsing with PBS, the sam-
ples were examined for the degree of biofilm removal by
observation under a confocal laser scanning microscopy
(CLSM). To analyze the effects of NAC on biofilms, 2
independent biofilm experiments were performed. From
each cover slip, 5 image stacks were acquired at different
positions; thus, 10 image stacks were analyzed for each
concentration of NAC. Images were acquired at 1 μm
intervals down through the biofilm and, therefore, the
number of images in each stack varied according to the
thickness of the biofilm. All microscopic observations
and image acquisitions used CLSM (Olympus FV1000,
Japan). Images were obtained with a 60× objective lens
and laser excitation at 488 nm. Z-series of optical sections
were reconstructed into three-dimensional images by
Olympus FV10-ASM 1.7 Software. Fluorescence inten-
sity in each fixed scanning area was measured.
The biofilm structure was quantified from the confocal
stacks using the image analysis software package COM-
STAT (kindly donated by A. Heydorn, Technical Univer-
sity of Denmark, Lyngby) [20]. This software can
interface with Matlab and utilizes Matlab's image analysis
software toolbox. COMSTAT offers an array of functions
and is capable of generating up to 10 different statistical
parameters for quantifying the 3-dimensional biofilm
structure. For this study, 7 COMSTAT parameters were
used to determine the differences between biofilms
grown under each of the 5 NAC concentrations. These
parameters were biomass, substratum coverage, maxi-
mum thickness, average thickness, surface area of bio-
mass, surface to volume ratio and roughness coefficient.
Detection of viable cells in biofilms using MTT assay
Dimethylthiazol diphenyltetrazolium bromide (MTT)
and extraction buffer were prepared as previously
described [26]. In brief, MTT was dissolved at a concen-
tration of 5 mg/ml in PBS. Extraction buffer was prepared
by dissolving 20% (wt/vol) sodium dodecyl sulfate (SDS)
at 37°C in a solution of 50% each of N,N-dimethylforma-
mide (DMF) and demineralized water; the pH was
adjusted to 4.7.
MTT assay. Twenty μl of the 5-mg/ml MTT stock solu-
tion was added to each well of a 96-well microtiter plate
(Costar, USA) containing 190 μl of bacteria. After incuba-
tion for 2 h at 37°C, 90 μl of extraction buffer was added
to each well. After thorough extraction, optical densities
were measured at 595 nm using a microplate reader
(Pulang New Technology Corporation, China).  MHB
(incubated with MTT and extraction buffer) was used as
a blank control. The assay was calibrated using series
dilutions of P. aeruginosa ATCC 27853 as standards,
which had been subjected to the same procedure.
TSB (2 ml) was dispensed in a 24-well microplate well
(Costar, USA) with a cut silicone sheet as a matrix for the
bacterial biofilm. Then, 50 μl of a bacterial suspension
(1.5 × 108 CFU/ml) was inoculated into the well and incu-
bated aerobically at 37°C for 6 days. The biofilm depos-
ited on a silicone sheet was gently rinsed with sterile
saline to remove bacterial cells, except for those included
in the biofilm. After rinsing, the biofilm was soaked in 1
of the following treatment solutions for 24 h at 37°C:
NAC (0, 0.5 mg/ml, 1 mg/ml, 2.5 mg/ml) and ciprofloxa-
cin (0, 1/2MIC, 1MIC, 2MIC, 4MIC, 8MIC) combina-
Table 3: Criteria of interpretation of biofilm production
Biofilm production average optical density 
(OD)
no biofilm producer ≤ ODc
weak biofilm producer ODc < ~ ≤ 2 × ODc
moderate biofilm producer 2 × ODc < ~ ≤ 4 × ODc
strong biofilm producer > 4 × ODc
Note: optical density cut-off value (ODc) = average OD of 
negative control + 3 × SD of negative control.
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sheets were rinsed 3 times with PBS to remove planktonic
bacteria, individually sonicated for 10 min and vortexed
for 3 min in 1 ml of MHB. The number of viable cells was
counted by the method described above. The lg (CFU)
per cubic centimeter values of sheets for different groups
were calculated.
Measurement of extracellular polysaccharides (EPS)
The amount of carbohydrates produced by each bacterial
strain was determined using a modified version of the
acid hydrolysis method of Dall and Herndon [27]. Briefly,
polysaccharides were precipitated with ethanol and then
dehydrated with concentrated acid to a furfural. When
tryptophan reacted with furfural, a condensation product
was formed, which developed a brownish violet color.
The amounts of EPS were determined spectrophotomet-
rically by measuring the absorbance at 490 nm.
Six-day old bacterial biofilms on silicone sheets, grown
as described above, were gently rinsed with PBS. After
rinsing, the biofilm was placed in alginate producing (AP)
medium described by Terry et al. [28] for 48 h, then
soaked in AP medium containing NAC (0, 0.5 mg/ml, 1
mg/ml) for an additional 24 h, gently rinsed with PBS to
remove bacterial cells, except for those included in the
biofilm, individually sonicated for 10 min and vortexed
for 3 min in 1 ml of PBS. The suspension was adjusted to
90% light transmittance at 400 nm (about 2.1 × 107 CFU/
ml), then centrifuged at 950 × g for 10 min, and the super-
natant was filtered through a sterile 0.22-μm membrane
filter. Then, 0.5 ml of the supernatant fluid, which con-
tained the polysaccharide, was precipitated by adding it
in drops to 4 ml of cold absolute ethanol. Polysaccharides
were pelleted by centrifugation (2,400 × g, 15 min) and
resuspended in 200 μl of distilled water, after which they
were digested with 700 μl of sulfuric acid (77%) to form
monosaccharides. Samples were cooled for 10 min in an
ice bath, then 0.1 ml of cold tryptophan (1%, wt/wt) was
added to each tube and mixed. After heating in a boiling
bath for 20 min, the tubes were cooled on ice, and the
absorbance at 490 nm was read with a spectrophotometer
(Pulang New Technology Corporation, China) using a
PBS blank subjected to the same procedure. The amount
of EPS was expressed in μg/μl. The assay was calibrated
using a dextran standard (Dextran T500, Pharmacia) sub-
jected to the same procedure.
Statistical analysis
Results were expressed as the means ± SD. One-way
ANOVA was used to compare groups; multiple compari-
sons used the Least-significant difference (LSD) method.
Analysis used SPSS 13.0 for Windows. P-values < 0.01
indicated significant differences.
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